Serina Therapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights
Serina Therapeutics, Inc. (SER)
Company Research
Source: GlobeNewswire
- FDA Grants IND Clearance for SER-252- SER-252 Phase 1b Trial Initiated- Closed Private Placement Financing of up to $30 Million HUNTSVILLE, March 25, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the "Company") (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today reported its financial results for the full year ended December 31, 2025 and provided recent business highlights. "This past year was defined by execution, advancing SER-252 from IND filing through FDA clearance, into the clinic while strengthening our balance sheet to support the clinical milestones ahead," said Steve Ledger, CEO of Serina. "With the first patient dosed in our registrational trial in advanced Parkinson's disease, and up to $30 million in new financing now secured, Serina enters 2026 with the clinical and financial foundation to reach meaningful value-creating inflection points. We are grateful to Dr.
Show less
Read more
Impact Snapshot
Event Time:
SER
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SER alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SER alerts
High impacting Serina Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SER
News
- Serina Therapeutics GAAP EPS of -$1.91, revenue of $0.13M [Seeking Alpha]Seeking Alpha
- Serina Therapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights [Yahoo! Finance]Yahoo! Finance
- Serina Therapeutics to Present at the 38th Annual Roth Conference [Yahoo! Finance]Yahoo! Finance
- Serina Therapeutics to Present at the 38th Annual Roth Conference [TheStreet.com]TheStreet.com
- Serina Therapeutics to Present at the 38th Annual Roth ConferenceGlobeNewswire
SER
Sec Filings
- 3/27/26 - Form 10-K/A
- 3/25/26 - Form S-8
- 3/25/26 - Form 8-K
- SER's page on the SEC website